Medication info
Liragenta Duo Tablet 2.5/1000 mg (Linagliptin Besylate, Metformin Hydrochloride)

Liragenta Duo Tablet 2.5/1000 mg (Linagliptin Besylate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
Pink, oval, biconvex, film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle - 30 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle - 60 tablets/bottle
Approval status
Active

MFDS item code 202401040 · Approved 2024.04.30

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current dose of metformin (for example, a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). Studies evaluating the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to assist blood sugar control in patients with type 2 diabetes who are suitable for combination therapy with Linagliptin and Metformin. When taken alongside diet control and exercise therapy, it helps to improve blood sugar levels more effectively. This can lead to better diabetes management and contribute to the prevention of complications.

How to take

Adult dose

The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients who have not previously received drug treatment for diabetes and whose blood glucose cannot be adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose is linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient’s current dose of metformin (for example, a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current dose of metformin. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Use with caution in the following patients). Studies evaluating the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine have not been conducted. Any change in the treatment regimen for type 2 diabetes may affect blood glucose control, so caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate [eGFR] 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication helps regulate blood sugar through the combined action of its two main ingredients. Caution is needed when taking this medication, as serious side effects such as lactic acidosis may occur. Lactic acidosis is a dangerous condition that results from an excessive buildup of lactate in the blood. If severe abdominal pain, muscle pain, lethargy, or shortness of breath occurs, consult a physician immediately. This medication should not be administered to certain patients, such as those who are allergic to this drug or its components, patients with type 1 diabetes, patients with severe renal impairment, patients experiencing acute heart disease or heart failure, patients with poor liver function, patients with severe dehydration or infections, and pregnant or nursing women, as it may pose risks. Furthermore, when used in conjunction with other diabetes medications that carry a risk of hypoglycemia, caution must be exercised to prevent blood sugar levels from becoming too low. Particularly, when combined with insulin or sulfonylurea medications, hypoglycemia symptoms should be closely monitored and dosage adjustments made if necessary. Elderly patients with declining kidney function or conditions that may alter renal function should be monitored regularly through blood tests for renal function. During treatment with this medication, acute pancreatitis or bullous skin diseases may occur. If severe abdominal pain, skin rash, or blisters develop, contact a physician immediately. This medication may cause gastrointestinal disturbances (such as abdominal pain, diarrhea, nausea, etc.), so it is advisable to take it with or after meals. Pregnant women or those planning to become pregnant should avoid this medication, and it is also recommended that breastfeeding women do not use it. This medication may interact with other drugs, so it is critical to inform your doctor or pharmacist of any currently taken medications, especially those that may affect kidney function or blood sugar-lowering agents. Finally, this medication is not recommended for use in children or those under 10 years of age, and dosage adjustments should be made for elderly patients considering renal function. Store this medication out of reach of children, avoid moisture, and do not transfer it to another container.

Side effects

Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, formation of oral ulcers, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular-like pemphigoid, severe joint pain accompanied by disability, rhabdomyolysis, increased lipase, increased amylase, constipation, abdominal pain, small and large bowel inflammation, bowel obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, speech disorder, Alzheimer's dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscal injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, palpitations, dry eye, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, dizziness, sensory loss, chest discomfort, myasthenia, itching, hypertension, benign prostatic hyperplasia, angina, acute myocardial infarction, unstable angina, diarrhea, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, anal bleeding, cheilitis, dental caries, enteritis, gastritis, dizziness, headache, drowsiness, altered mental status, nocturia, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should ideally be maintained between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink, oval, biconvex, film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle - 30 tablets/bottle, 30 tablets/bottle, 60 tablets/bottle - 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.